Cart
sales@molnova.com
Plozalizumab
CAS No. 1610761-46-0
Plozalizumab( —— )
Catalog No. M36823 CAS No. 1610761-46-0
Plozalizumab (MLN-1202) is a humanized, selective, and potent anti-CCR2 antibody with antitumor activity, used in the study of malignant melanoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 565 | Get Quote |
|
| 5MG | 943 | Get Quote |
|
| 10MG | 1492 | Get Quote |
|
| 25MG | 2144 | Get Quote |
|
| 50MG | 2898 | Get Quote |
|
| 100MG | 3825 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePlozalizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPlozalizumab (MLN-1202) is a humanized, selective, and potent anti-CCR2 antibody with antitumor activity, used in the study of malignant melanoma.
-
DescriptionPlozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. Plozalizumab can be used for malignant melanoma research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetCCR
-
RecptorCCR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610761-46-0
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jahchan NS, et al. Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Front Immunol. 2019 Jul 25;10:1611.?
molnova catalog
related products
-
Maraviroc
Maraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM, respectively.
-
Cenicriviroc
Cenicriviroc is an orally active, dual antagonist of CCR2/CCR5. It also inhibits both HIV-1 and HIV-2, and displays potent anti-infective and anti-inflammatory activity.
-
CCR6 antagonist 1
CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).
